Article Text

PDF

21 Impact of Combined Atrial Fibrillation and Heart Failure on Mortality: 14 Year Naturalistic Follow-Up Study
  1. Oliver Ziff1,
  2. Paul R Carter2,
  3. John McGowan3,
  4. Suresh Chandran4,
  5. Hardeep Uppal5,
  6. Rahul Potluri6
  1. 1University of Birmingham
  2. 2Royal Free London NHS Foundation Trust
  3. 3Central Manchester University Foundation Trust
  4. 4Department of Acute Medicine, North Western Deanery
  5. 5ACALM Study Unit in Collaboration with Aston Medical School
  6. 6ACALM Study Unit in Collaboration with Aston Medical School, Aston University

Abstract

Background Atrial Fibrillation (AF) and Heart Failure (HF) frequently co-exist conferring considerable morbidity and mortality, yet current treatment options remain limited. Recent meta-analyses of patients with concomitant AF and HF have suggested no prognostic benefit of beta-blockers or digoxin, creating a paradox whereby those most in need have the fewest therapeutic choices. We sought to investigate the association between HF and AF and their impact on mortality from a large 14-year naturalistic follow-up study.

Methods Anonymous data of adult patients aged ≥18 with all types of HF and AF admitted to several hospitals in the North of England between 2000 and 2013 was obtained and processed using the ACALM (Algorithm for Co-morbidity, Associations, Length of stay and Mortality) study protocol. ACALM uses the ICD-10 and OPCS-4 coding systems to identify patients and the methodology has been published widely. Analyses were performed comparing mortality between patients with HF, AF and combined HF and AF at baseline and their development during follow-up.

Results At baseline, of 929,552 adult patients 29,164 (3.1%) had AF, 19,474 (2.1%) had HF, and 5,728 (0.6%) had both HF and AF. Of those with AF at baseline, 1,647 (5.6%) developed HF during follow-up, and of those with HF at baseline, 824 (4.2%) developed AF during follow-up. Demographics and crude mortality rates are shown; see Table. Patients with combined AF and HF at baseline had increased mortality than patients with AF or HF alone. Patients with AF at baseline that developed HF, and patients with HF at baseline that developed AF, experienced a greater mortality compared to those with combined HF and AF at baseline; see Figure.

Abstract 21 Table 1

Characteristics of ACLM participants by atrial fibrillation and heart failure status at the start and end of the study

Abstract 21 Figure 1

Kaplan Meier survival curves through the duration of follow-up in the ACALM database are shown based on atrial fibrillation and heart failure status at the start and end of the study. AF, atrial fibrillation; HF, heart failure

Conclusion Concomitant AF and HF is associated with substantial mortality and risk of death, irrespective of which disease develops first. In light of limited current treatment for these patients, future therapies to specifically target the combined HF and AF group are required.

  • Heart Failure
  • Atrial Fibrillation
  • All-cause mortality

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.